Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children

Riccardo Masetti, Francesca Vendemini, Paola Quarello, Katia Girardi, Arcangelo Prete, Franca Fagioli, Andrea Pession, Franco Locatelli

Research output: Contribution to journalArticlepeer-review

Abstract

Persistent thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (HSCT). While the use of thrombopoietin receptor agonists was retrospectively investigated in adults, data in pediatric posttransplant thrombocytopenia are lacking. We evaluated the safety and efficacy of eltrombopag in nine children with platelet transfusion-dependent persistent thrombocytopenia after HSCT. Eltrombopag was started at a median of 147 days after allo-SCT and continued for a median period of 64 days, the starting dose being 50 mg per day. The therapy was well tolerated. After a median time of treatment of 36 days, eight patients (88%) reached sustained platelets count >50 000/μL.

Original languageEnglish
Article numbere28208
JournalPediatric Blood and Cancer
Volume67
Issue number5
DOIs
Publication statusPublished - May 1 2020

Keywords

  • eltrombopag
  • pediatric hematopoietic stem cell transplantation
  • thrombocytopenia
  • thrombopoietin receptor agonists

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children'. Together they form a unique fingerprint.

Cite this